Kestra Medical Technologies, Lt (KMTS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Kestra Medical Technologies, Lt

NasdaqGS•Healthcare•Medical Instruments & Supplies

$24.74+0.68(0.03%)Market open

Market Cap

$1.41B

P/S

13.2x

P/B

6.3x

Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. Its platform provides ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected; digital patient engagement and clinical workflow solutions designed to improve patient adherence, support care coordination, and provide actionable clinical insights throughout the recovery process; and integrated platform generates continuous cardiac rhythm data and clinically actionable insights. Kestra Medical Technologies, Ltd. was founded in 2014 and is based in Kirkland, Washington.

How this company scores

WeakMetricSide Score: 34/100

Grade capped at D — Interest coverage below 1× (-18.6x) — earnings cannot cover interest. Strongest: Balance Sheet & Red Flags (11/25); weakest: Cash & Earnings Quality (6/25).

Profitability7/25

Growth10/25

Balance Sheet & Red Flags11/25

Cash & Earnings Quality6/25

Strengths

Low leverageConsistent growthImproving margins

Grade capped at D

Interest coverage below 1× (-18.6x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 13.2x5y range 11.9x – 14.1x

Currently near its 4-quarter median.

P/B · 6.3x5y range 2.9x – 8.8x

Currently above its 6-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 7 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.41B

Metrics at a Glance

as of July 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $106.73M
Q. Revenue: $30.97M
TTM EBITDA: $-134.18M
TTM Op. Income: $-143.52M
Q. Op. Income: $-37.66M
TTM Net Income: $-149.87M
Q. Net Income: $-44.09M
EPS: $-0.75
Shares Out.: $58.57M

$106.73M in TTM revenue grew from zero YoY, reaching $30.97M last quarter. TTM EBITDA of $-134.18M and TTM operating income of $-143.52M show growth is flowing through to the bottom line. However, net income is negative at $149.87M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 0% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 56.5%
EBITDA Margin: -113.0%
Op. Margin: -121.6%
Net Margin: -142.3%

Op. margin of -121.6% is up 27.5% YoY — cost efficiency is improving. Net margin at -142.3% and gross margin of 56.5% show how much of each revenue dollar survives to profit. Across the last 7 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 13.2x
P/B Ratio: 6.3x

P/S of 13.2x and P/B of 6.3x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $347.36M
Cash: $68.56M
Long-Term Debt: $72.50M
Book Value: $222.36M
D/E Ratio: 0.3
Debt/EBITDA: N/A

With $347.36M in assets and $72.50M in long-term debt, D/E is 0.3and book value is $222.36M — a conservative capital structure with a cushion to weather downturns. Across the last 6 quarters, debt/equity has risen for 2 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-32.30M
TTM Free Cash Flow: $-122.78M
FCF Margin: -115.0%
FCF / Net Income: 0.8

TTM FCF of $-122.78M on $-32.30M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 0% — a weakening trend.